Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.